Ross Kedl, PhD

AURORA, Colo. (Nov. 3, 2009) – ImmuRx, co-founded by Ross Kedl, PhD, assistant professor in the department of Immunology at the University of Colorado Denver School of Medicine, has been awarded a $577,000 Small Business Innovation Research (SBIR) award from the National Institutes of Health (NIH) to study the potential of the ImmuRx platform to treat tuberculosis (TB).

ImmuRx is developing a platform of drug products that stimulate the immune system for the treatment of cancer and chronic infectious diseases such as TB. The company’s platform is based on intellectual property (IP) licensed from the University of Colorado and Dartmouth College.

A major part of the TB work will be done in two Colorado laboratories. Kedl’s laboratory at the University of Colorado Denver will optimize the immunological properties. Dr. Angelo Izzo, of Colorado State University’s Mycobacteria Research Laboratories, will test whether the approach protects against TB. The entire program is expected to take two years.

“The immune system is like a lock that requires two keys – and ImmuRx provides them both,” said Kedl. “Current adjuvant products stimulate only one half of the immune system. The ImmuRx platform stimulates both the innate and adaptive halves. The result is synergy which dramatically enhances efficacy and safety.”

The competitive advantage of the platform has been demonstrated in animal models of a variety of diseases, each representing a large class of addressable markets: solid tumors such as melanoma and lung; hematologic cancers such as lymphoma; and chronic viral and bacterial infectious diseases such as hepatitis C, TB and possibly HIV.

Faculty at the University of Colorado Denver’s School of Medicine work to advance science and improve care. These faculty members include physicians, educators and scientists at University of Colorado Hospital, The Children’s Hospital, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. Degrees offered by the CU Denver School of Medicine include doctor of medicine, doctor of physical therapy, and masters of physician assistant studies. The School is located on the University of Colorado’s Anschutz Medical Campus, one of four campuses in the University of Colorado system. For additional news and information, please visit the CU Denver newsroom online.

ImmuRx is an early stage company developing a platform of drug products that stimulate the immune system. Broad patent claims are issued that enable ImmuRx to unlock the potential of the immune system to treat a wide variety of diseases including cancer and chronic infectious disease. ImmuRx has assembled a team with experience in business development, patent protection, drug discovery and human clinical trial execution required to bring this opportunity forward. The breadth of the patent portfolio provides many opportunities for success and a deep pipeline to develop.

Contact: Caitlin Jenney, 303.315.6376, [email protected]

Office of University Communications

CU Anschutz
Building 500

13001 East 17th Place

Room CG009

Aurora, CO 80045